PET and MRI Imaging With Scopolamine at the Muscarinic M1 Receptor

计划入组 6 人 · 首次发布于 2023 年 8 月 28 日

M1 Schizophrenia PET Study

计划入组 18 人 · 首次发布于 2021 年 11 月 3 日

Sanctura Muscarinic Receptor Antagonist Resists Transport (SMART) Trial

计划入组 12 人 · 首次发布于 2009 年 3 月 18 日

M4-PAM

Acetylcholine(Miochol)

C₇H₁₆NO₂

SUVN-L1305022

Arvinas Estrogen Receptor, Inc.

United States

Arvinas Androgen Receptor, Inc.

United States

Veru Inc

United States

First In Vivo PET Evidence Reveals Widespread M1 Receptor Deficits in Living Schizophrenia Patients

FDA Clears IND for Neurocrine and Nxera's Oral M1 Agonist NBI-1117567 in Alzheimer's Cognition

MapLight Therapeutics Initiates Phase 2 Trial of Novel M1/M4 Muscarinic Agonist ML-007C-MA for Schizophrenia Treatment